Skip Navigation


European Heart Journal Advance Access originally published online on August 15, 2006
European Heart Journal 2006 27(18):2247-2255; doi:10.1093/eurheartj/ehl198
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
27/18/2247    most recent
ehl198v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fadini, G. P.
Right arrow Articles by Avogaro, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fadini, G. P.
Right arrow Articles by Avogaro, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk

Gian Paolo Fadini1, Saula Vigili de Kreutzenberg1, Anna Coracina1, Ilenia Baesso2, Carlo Agostini2, Antonio Tiengo1 and Angelo Avogaro1,*

1 Department of Clinical and Experimental Medicine, Division of Metabolic Diseases, University of Padua, Medical School, Padua, Italy
2 Department of Clinical and Experimental Medicine, Immunology and Hematology Branch, University of Padua, Medical School, Padua, Italy

Received 14 December 2005; revised 29 June 2006; accepted 27 July 2006; online publish-ahead-of-print 15 August 2006.

* Corresponding author. Dipartimento di Medicina Clinica e Sperimentale, Divisione di Malattie del Metabolismo, Policlinico Universitario, v. Giustiniani 2, 35100 Padova, Italy. Tel: +39 049 8212185; fax: +39 049 8212184. E-mail address: angelo.avogaro{at}unipd.it

Aims Circulating progenitor cells are believed to participate in cardiovascular (CV) homeostasis and their exhaustion has been linked to CV damage. As general agreement on their characterization is lacking, this work was carried out to assess the relationships between different antigenic profiles of progenitor cells and CV risk, with special regard to metabolic syndrome (MetSyn).

Methods and results CD34, CD133, and KDR were used to quantify circulating progenitors in 214 subjects at different levels of CV risk. In a cross-analysis of six different cell subtypes (CD34+, CD133+, CD34+CD133+, CD34+KDR+, CD133+KDR+, and CD34+CD133+KDR+), CD34+ progenitors showed the best correlation with CV parameters and risk estimates. Components of the MetSyn were all characterized by reduction of CD34+ cells and acted synergistically in decreasing CD34+ cell count. Moreover, CD34+ cell count demonstrated a high performance in detecting high CV risk.

Conclusion These data demonstrate that CD34 identifies progenitor cells linked to CV risk, showing a close negative correlation between CD34+ cells and CV risk, as well as a synergic detrimental effect of clustered metabolic components. Progenitor cell count may be used as a surrogate marker of CV risk, whereas extensive antigenic characterization may not be useful for this purpose.

Key Words: Endothelial progenitor cells • Stem cells • Cardiovascular risk • Metabolic syndrome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
A. A van der Klaauw, A. M Pereira, T. J Rabelink, E. P M Corssmit, A.-J. Zonneveld, H. Pijl, H. C de Boer, J. W A Smit, J. A Romijn, and E. J P de Koning
Recombinant human GH replacement increases CD34+ cells and improves endothelial function in adults with GH deficiency
Eur. J. Endocrinol., August 1, 2008; 159(2): 105 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
G. P. Fadini, S. de Kreutzenberg, M. Albiero, A. Coracina, E. Pagnin, I. Baesso, A. Cignarella, C. Bolego, M. Plebani, G. B. Nardelli, et al.
Gender Differences in Endothelial Progenitor Cells and Cardiovascular Risk Profile: The Role of Female Estrogens
Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 997 - 1004.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. P. Fadini, I. Baesso, C. Agostini, E. Cuccato, G. B. Nardelli, A. Lapolla, and A. Avogaro
Maternal Insulin Therapy Increases Fetal Endothelial Progenitor Cells During Diabetic Pregnancy
Diabetes Care, April 1, 2008; 31(4): 808 - 810.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Okada, H. Makino, A. Nagumo, T. Sugisawa, M. Fujimoto, I. Kishimoto, Y. Miyamoto, A. Kikuchi-Taura, T. Soma, A. Taguchi, et al.
Circulating CD34-Positive Cell Number Is Associated With Brain Natriuretic Peptide Level in Type 2 Diabetic Patients
Diabetes Care, January 1, 2008; 31(1): 157 - 158.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
G. P. Fadini, S. Sartore, C. Agostini, and A. Avogaro
Significance of Endothelial Progenitor Cells in Subjects With Diabetes
Diabetes Care, May 1, 2007; 30(5): 1305 - 1313.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. Sanz, P. R. Moreno, and V. Fuster
The Year in Atherothrombosis
J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1740 - 1749.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
G. P. Fadini, C. Agostini, and A. Avogaro
Endothelial progenitor cells and erectile dysfunction
Eur. Heart J., March 1, 2007; 28(5): 639 - 640.
[Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
G. L. Hoetzer, G. P. Van Guilder, H. M. Irmiger, R. S. Keith, B. L. Stauffer, and C. A. DeSouza
Aging, exercise, and endothelial progenitor cell clonogenic and migratory capacity in men
J Appl Physiol, March 1, 2007; 102(3): 847 - 852.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.